Pfizer has published new clinical data that demonstrates the benefits its pneumococcal disease vaccine Prevnar 13 can offer to older children and adolescents.
Results from the latest phase III trial of the drug have shown that it was able to meet all study endpoints following assessment among children and adolescents aged between five and 17 years old, providing immunogenicity and a strong safety profile.
Originally introduced in Europe in December 2009 as a treatment for infants and small children, the vaccine is now available in more than 110 countries.
This new data will support Pfizer's plan to file for regulatory approval of an expanded indication of Prevnar 13 in the US, Europe and other regions.
Dr Emilio Emini, chief scientific officer for vaccine research at Pfizer, said: "We are excited about the potential to further define the clinical utility of Prevnar 13 with the aim of seeking to broaden prevention efforts to additional age groups."
This comes after the vaccine was approved for use among adult patients aged over 50 in the US earlier this year.See all the latest jobs in Pharmaceutical